MedTrace Logo

Bazedoxifene -Treatment for Women With Schizophrenia

NCT04113993 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-11-28

No results posted yet for this study

Summary

To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.

Conditions

  • Schizophrenia
  • Schizophreniform Disorders
  • Schizo Affective Disorder

Interventions

DRUG

Bazedoxifene Acetate

Oral Bazedoxifene dosed at 40 mg daily for 12 weeks

DRUG

Placebo

Identically packaged placebo capsule daily

Sponsors & Collaborators

  • Monash University

    collaborator OTHER

  • Monash Health

    collaborator OTHER

  • The Alfred

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-07
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04113993 on ClinicalTrials.gov